Overview

Voxelotor Cerebral Hemodynamics Study

Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the impact of voxelotor treatment on cerebral blood flow (CBF) in adult and adolescent participants (12-30 years of age) with sickle cell disease (SCD).
Phase:
Phase 4
Details
Lead Sponsor:
Global Blood Therapeutics